Alzheimer's disease affects an ever-increasing number of people in the aging population.
. As the literature also quickly shows, it seems possible to apply photobiomodulation to the brain transcranially, for which even more different terms and abbreviations exist. Figure 1 provides an overview to the multiple terms describing the same technique.
Figure 1: There are many names used for the use of light in medical applications, which can all be grouped under the umbrella term of photobiomodulation. Used against Alzheimer's disease the method utilizes comparatively low power, or low level, near-infrared laser or LED light which can be applied in a transcranial manner for photoneuro-modulation [9].
As Table 1 shows, reducing the literature search to the MeSH terms "Photobiomodulation"
and "Alzheimer's disease" falls a long way short of what can be found when performing a query containing a combination of all search terms from Figure 1 and identifiers for Alzheimer's disease and dementia. There was just one obvious mismatch when using the Enengl broader search term and it was easy to identify when "NILT" was found to be used as an abbreviation for "Northern Ireland Life and Times". Combination of terms from Obvious mismatch 1 0
The 5 Review articles [10] [11] [12] [13] [14] come to the conclusion, that photobiomodulation with low level red to near infrared light offers a compelling method against neurodegeneration.
Literature Summary
Photobiomodulation (PBM) is defined as the use of monochromatic or quasi-monochromatic light from a low power laser or LED source to modify or modulate biological functions. Such a modulation is based on the presence of chromophores in cells and tissues. These chromophores are molecules capable of absorbing light, whose excitation can influence further molecules and biochemical pathways with the potential for a therapeutic effect [15] .
The target molecule of PBM, mainly discussed in literature, lies within Complex IV (cytochrome c oxidase) of the mitochondrial respiration system. Photons that interfere with the cytochrome oxidase enzyme in the NIR frequency range are absorbed, essentially acting as an exogenous supply of highly energized electrons to the mitochondrial respiratory chain.
Following this immediate, primary effect, the increase in cytochrome oxidase activity triggers secondary effects by activating enzymatic pathways which are coupled to the mitochondria's Enengl, Dungel #neverforget -PBM vs AD: A Systematic Review
Page 6 of 25 role in energy metabolism, cell homeostasis, and cell survival signaling. The secondary effects of photobiomodulation amplify the primary effects by upregulating the levels of cytochrome oxidase and thus creating more of the target molecule for PBM [13, 16] .
The energy density delivered by PBM is generally too low to cause concerns about heating and tissue destruction [17] , and it appears to be safe even when applied long term [18] . As a treatment option for head and neck pain, for treatments of arthritis, and for carpal tunnel syndrome, PBM was shown to have an efficacy beyond the placebo effect, [19] , which lead to the first FDA-approved low-level light therapy devices for pain relief [20] .
Interest in the use of photobiomodulation for neuro-rehabilitation is growing and it has already shown potential in treating traumatic brain injury, stroke, psychiatric disorders, as well as neurodegenerative disease in general [21] [22] [23] .
Transcranial Photobiomodulation with Red to Near

Infra-Red Light
To make PBM work on the brain, one can benefit from the optical tissue window which allows 
Molecular Mechanisms of Photobiomodulation and their Implications for Alzheimer's Disease
The impact of photobiomodulation on cell culture and animal models of Alzheimer's disease has been extensively studied. A summary of the progress on each stage of development from basic research to preclinical and clinical Phase I and II trials is presented to form the base for a treatment plan.
2..1.1 PBM and AD in vitro
Sommer et al report that photobiomodulation reduces amyloid beta (Aβ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] ) aggregates in human neuroblastoma cells [28] and Yang et al observed a reduction in amyloid beta induced oxidative and inflammatory responses in rat primary cortical astrocytes [29] . Looking [35, 36] . Weekly treatments of PBM with a dose of 1 J/cm² applied to the bone marrow of AD-mice iappears to increase the MSCs ability to phagocytose Aβ-proteins in the brain, which leads to improved cognitive capacity and spatial learning after a total treatment duration of 2 months, compared to a sham-treated control group. This is an interesting observation, albeit outside the scope of this review, since it builds not on the effect of PBM on braincells directly, but rather secondary effects through stimulation of et al demonstrated histochemical evidence of a beneficial effect [37] . NFTs, hyperphosphorylated tau-protein, and oxidative stress markers were reduced to near wildtype levels and PBM treatment also reduced Aβ-plaques in both number and in size.
De Taboada et al used a GaAIAs diode laser with a wavelength of 808 nm ± 10 nm to deliver increasing doses, from 4.8 J/cm² (1.2 J/cm² at cortical surface) to 48 J/cm² (12 J/cm² at cortical surface), three times per week for a total duration of six months on transgenic mice engineered to develop Aβ-plaques [38] . Their results show an attenuation of amyloid development, leading to the conclusion that an early and regular administration of PBM has the potential to halt progression from MCI to AD.
Applications of Transcranial Photobiomodulation on Human Subjects Supporting its Therapeutic Value for Neurological Use
In an opinion article by Gonzalez-Lima and Barret [17] , the authors summarize how the development of photobiomodulation (PBM) has evolved over the last 40 years to a point where it is beginning to be used for cognitive-enhancing applications.
They built a placebo controlled study focusing on the beneficial cognitive and emotional effects in humans upon this opinion, and already two weeks after a single therapy session a significant improvement was observed [39] . These beneficial effects are reflected in improvements in reaction time in a sustained-attention psychomotor vigilance task (PVT), in a delayed match-to-sample memory task (DMS), and a self-reported Positive and Negative
Affect Schedule (PANAS-X). Blanco et al then used the Wisconsin Card Sorting Task
(WCST) directly after receiving the PBM treatment to assess the effects of transcranial infrared laser stimulation on executive function in a placebo controlled study on healthy human participants [40] . Here, low level laser light at a wavelength of 1064 nm and power density of 250 mW/cm² was applied to two locations on the right portion of the forehead for a total of four minutes per site. The total supplied dose of this study again corresponds to the ones stated above, being 60 J/cm² per site, and the treatment group performed significantly better than the control group during a WCST performed. Schiffer et al report beneficial effects of transcranial PBM on anxiety and depression after a study in which PBM with an LED array with a peak wavelength at 810 nm and an energy density of also 250 mW/cm² was used [41] . They calculated that from the supplied dose of 60 J/cm² at the scalp, an effective 2.1 J/cm² (3.7 %) reached the dura of the brain. Positive effects of a single treatment session compared to a placebo control group were observed two weeks after PBM, which waned off by the time of a further assessment after four weeks.
As stated by Hashimi et al in their article about the role of PBM in neurorehabilitation [21] , transcranial photobiomodulation with low level red to near infrared light has already been used on human subjects with moderate Alzheimer's disease, although no peer reviewed publications exist as of yet. This is slowly changing, with new devices being developed and more individuals being treated [42, 43] .
Minimum Effective and Maximum Tolerated Dose
When red-to-near-infrared monochromatic or quasi-monochromatic light is supplied to the cytochrome oxidase in neuronal mitochondria, the photons from this light influence the proton gradient of the mitochondrial membrane and thus modulate ATP production. The effective dose of PBM appears to follow the principle of hormesis, meaning that low doses are stimulatory while higher doses are less effective or even counterproductive. The minimum effective and maximum tolerated dose has been experimentally evaluated in vitro and in vivo, the translation of these results to transcranial application on humans is supported by results from studies on transmission factors and penetration depth of red and NIR light in intermediate tissue.
Hormesis
The hermetic effect of PBM was shown by Gonzalez-Lima and Barrett in a study on rats,
where 660 nm LED arrays with a power density of 9 mW/cm² showed the highest increase in cytochrome oxidase activity at a dose of 10.9 J/cm² (13.6 % increase), slightly less at the higher dose of 21.6 J/cm² (10.3 % increased activity) and finally a point of only non-
(1) significant activity increase (3 %) at the highest dose of 32.9 J/cm² [17] . Using fluorescencequenching to measure neuronal oxygen consumption by looking at oxygen concentration in the cortex, Rojas et al report a 5 % increase in oxygen consumption at 1 J/cm² and a 16 % increase at a dose of 5 J/cm² when using PBM with 660 nm and an energy density of 9 mW/cm² on rats [44] .
Transmission
Tedford et al quantitatively analyzed the amount of light that reaches the brain by using human cadaver heads, which they sectioned in such way that all of the intermittent tissues were kept intact and the optical energy was measured "on site" within the brain [24] . Results
show an exponential increase in fluence rates with a linear decrease in distance between measurement probe and light source. An absorption coefficient for each of the measured wavelengths is also provided which can then be used to calculate the dose supplied to any point inside the brain using equation (1) Table 2 shows [46] . Bungart et al investigated different wavelengths for transcranial PBM and came to the conclusion that a combination of 660 nm and 810 nm provides superior penetration compared to a combination of 980 nm and 1064 nm [26] .
Once the light reaches the inside of the skull, the depth of penetration is limited by the optical properties of the brain tissue. Table 3 shows an excerpt of the results from Stolik et al's ex vivo, post mortem measurements of the penetration depths of red and near infrared light in brain tissue, which suggest that light with longer wavelength will penetrate deeper into the tissue [47] . To investigate which wavelength within the optical tissue window will penetrate the deepest and deliver the highest dose, the values for the tissue absorption coefficient as well as the penetration depth were extracted from [24] and [47] and extrapolated by use of polynomial trend lines as shown in Figure 3 . While Figure 3 suggest that a wavelength between 700 nm and 830 nm is likely to have the most effective and also the deepest delivery of light energy to areas inside the brain, an article by Wu et al claims that illumination with 730 nm and 980 nm appears to be ineffective when used as a modality for traumatic brain injury in mice and they suggest to use a mix of Energy Density and Dosage
Summing up the available body of research on PBM to the brain, an application time long enough to achieve a dose in the minimum effective range between 5 -10 J/cm² is needed on a neuronal level, so, considering the exponential energy decrease during transcranial application, energy densities of 60 J/cm² applied to the human scalp are suggested. With an energy density of 250 mW/cm² this dose can be delivered within 4 minutes while PBM with a device supplying 100 mW/cm² would be able to deliver the required dose in 10 minutes.
Outlook on a Study Design
As a randomized, controlled, clinical intervention study, the focus needs to be on individuals who are at particular, specific risk to develop Alzheimer's disease (AD), or at an early stage with evidence of AD neuropathology [49] . A stagnation of the MMSE-score of the treatment group can be chosen as the most easily detectable primary endpoint of the study. It is expected that the MMSE-score of the control group falls by 2 -5 points per year [50] .
To reach sufficient power and significance of the study, at least 15 participants per group will be required when assuming that the MMSE-scores of treatment-and control group differ by should be taken into account by recruiting twice as many participants than were calculated to be sufficient, resulting in a minimum n = 30 per group.
To achieve a higher sensitivity for any changes during the treatment protocol it is suggested to supplement the standard MMSE by a more sophisticated neuropsychological test battery.
One such option could be the CERAD-NP- [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] . The pathophysiological assessment with MRI at the start of the study is useful to support the diagnosis of early AD. A second MRI at the end of the treatment period might provide more useful in combination with a sensitive algorithm that can reliably detect a change in brain atrophy, for example the automated MRI assessment by Desikan et al which has already demonstrated its usefulness as a diagnostic marker for mild cognitive impairment (MCI) and AD [62] .
Conclusion
When comparing the specifications of PBM devices used in the available literature, especially wavelength and intensity, a very inhomogeneous picture is created. One thing that is clear, however, is that the optical window for deep tissue penetration suggests best results at wavelengths in the far red and near infrared range, e.g. at 810 nm. The irradiation intensity of such a device needs to allow delivery of a dose of up to 60 J/cm² to the scalp within a reasonable period of time while providing an energy density below the risk of thermal damage. The amalgamation of the available literature as presented in this systematic review allows the assumption that photobiomodulation with the right settings can be a useful tool in the fight against Alzheimer's disease. Study protocols for large placebo-controlled studies are readily available and we should be able to get significant results with representative statistical power within a year. The time to act is now -lest we forget.
